Page last updated: 2024-09-04

vatalanib and enzastaurin

vatalanib has been researched along with enzastaurin in 3 studies

Compound Research Comparison

Studies (vatalanib)	Trials (vatalanib)	Recent Studies (post-2010) (vatalanib)	Studies (enzastaurin)	Trials (enzastaurin)	Recent Studies (post-2010) (enzastaurin)
276	42	98	188	52	99

Protein Interaction Comparison

Protein	Taxonomy	enzastaurin (IC50)
Protein kinase C gamma type	Homo sapiens (human)	0.7915
Protein kinase C alpha type	Rattus norvegicus (Norway rat)	0.7
Protein kinase C beta type	Homo sapiens (human)	0.1797
Protein kinase C delta type	Rattus norvegicus (Norway rat)	0.7
Protein kinase C epsilon type	Rattus norvegicus (Norway rat)	0.7
Protein kinase C zeta type	Rattus norvegicus (Norway rat)	0.7
Protein kinase C alpha type	Homo sapiens (human)	0.4695
Protein kinase C eta type	Homo sapiens (human)	0.4
Protein kinase C gamma type	Rattus norvegicus (Norway rat)	0.7
Protein kinase C beta type	Rattus norvegicus (Norway rat)	0.7
Protein kinase C epsilon type	Homo sapiens (human)	0.38
Protein kinase C zeta type	Homo sapiens (human)	8
Protein kinase C delta type	Homo sapiens (human)	1
Calcium/calmodulin-dependent protein kinase type II subunit beta	Homo sapiens (human)	10
Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)	10
Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)	10
Protein kinase C eta type	Rattus norvegicus (Norway rat)	0.7
Calcium/calmodulin-dependent protein kinase type II subunit alpha	Homo sapiens (human)	10
Protein kinase C theta type	Rattus norvegicus (Norway rat)	0.7

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP	1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP	1
Anderson, KC; Podar, K	1

Reviews

1 review(s) available for vatalanib and enzastaurin

Article	Year
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Current cancer drug targets, 2011, Volume: 11, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway	2011

Article

Year

Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.

Current cancer drug targets, 2011, Volume: 11, Issue:9

Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway

2011

Other Studies

2 other study(ies) available for vatalanib and enzastaurin

Article	Year
Comprehensive analysis of kinase inhibitor selectivity. Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11 Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity	2011
The target landscape of clinical kinase drugs. Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays	2017

Article

Year

Comprehensive analysis of kinase inhibitor selectivity.

Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011

The target landscape of clinical kinase drugs.

Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017